| novo norkdisk R&D Pipeline zhion@zhion.com November 30, 2005 |
PHARMCEUTICAL
INDUSTRY
Foundamental
Science
Colloidal
Stabilization
Drug Product
Development
Patent Application
Product
Development
Product
Ingredients
Colorant
Scale up a batch 1
Drug Delivery
Industry
Drug Delivery -
Smart Bomb
Lotion, Cream,
Preps
Enteric
Coating-Eudragit
Enteric
Coating-Nutrateric
SR
Coating-Aquacoat
Drug Industry
Drug
Competitions
Drug in
Development
Cholesterol-lowering
Drug-Terminologies
Packaging
Materials
Market
Drug Dev- 2004
Drug Dev -
2005Q1
Drug Dev- 2005Q2
Drug
Dev-2005Summer
Drug Dev-2005Q3
Orphan Drug
Protein Drug
Niche Market
Novo Norkdisk
R&D
Equipment
Blenders
CONTRACT
MANUFACT.
Nutrition
Supplements
NEW DRUGS
Arranon
Actoplus Met
Alfuzosin
Ambien CR
Avastin
Asmanex(R)
Erbitux
(cetuximab)
Gardasil
GRN163
Herceptin
Increlex (rhIGF-1)
Lidoerm
(Lidocaine)
Liraglutide
Lyrica (pregabalin)
Rozerem
Sorafenib
Sutent
Tamsulosin
Torcetrapib
Zometa
OLD DRUGS
Lithium Carbonate
DRUG NOTES
[CONSTRUCT]
Clinical Research
Terminologies
FDA ALERTS
Protein Drug
Market
Niche Market
Orphan Drug
levothyroxine
Protein Drug 1
Protein Drug2
Double-blind
Study
INDUSTRY
Foundamental
Science
Colloidal
Stabilization
Drug Product
Development
Patent Application
Product
Development
Product
Ingredients
Colorant
Scale up a batch 1
Drug Delivery
Industry
Drug Delivery -
Smart Bomb
Lotion, Cream,
Preps
Enteric
Coating-Eudragit
Enteric
Coating-Nutrateric
SR
Coating-Aquacoat
Drug Industry
Drug
Competitions
Drug in
Development
Cholesterol-lowering
Drug-Terminologies
Packaging
Materials
Market
Drug Dev- 2004
Drug Dev -
2005Q1
Drug Dev- 2005Q2
Drug
Dev-2005Summer
Drug Dev-2005Q3
Orphan Drug
Protein Drug
Niche Market
Novo Norkdisk
R&D
Equipment
Blenders
CONTRACT
MANUFACT.
Nutrition
Supplements
NEW DRUGS
Arranon
Actoplus Met
Alfuzosin
Ambien CR
Avastin
Asmanex(R)
Erbitux
(cetuximab)
Gardasil
GRN163
Herceptin
Increlex (rhIGF-1)
Lidoerm
(Lidocaine)
Liraglutide
Lyrica (pregabalin)
Rozerem
Sorafenib
Sutent
Tamsulosin
Torcetrapib
Zometa
OLD DRUGS
Lithium Carbonate
DRUG NOTES
[CONSTRUCT]
Clinical Research
Terminologies
FDA ALERTS
Protein Drug
Market
Niche Market
Orphan Drug
levothyroxine
Protein Drug 1
Protein Drug2
Double-blind
Study
Novo Nordisk
Novo Nordisk was created in 1989 through a merger between two
Danish companies: Novo Industri A/S and Nordisk Gentofte A/S. In
1941, Novo launches its first enzyme, trypsin, extracted from the
pancreas of animals and used for bating leather before tanning. In 1946,
Nordisk develops Isophane insulin (NPH), a neutral insulin with
prolonged action. In 1947 Novo Norkdisk luanched its first
fermentation product Penicillin Novo. In 1953, Nova Nordisk lauched
Lente - a long-acting insulin suspension. In 1973, Novo Norkdisk
marketed Nanormon growth hormone for the treatment of growth
hormone insufficiency. It also introduced Monocomponent (MC) insulin.
In 1982, Novo Norkdisk launched human monocomponent insulin - the
first insulin preparation idential to human insulin. It is extracted from the
pancreas of pigs and converted to human insulin. In the last two
decades, they developed and launched various products including
NovoPen (an injection system, Norditropin (genetically engineered
human growth hormone), NovoLet (prefilled insulin syringe),
NovoSeven (treatment of haemophilia), NovoNorm/Prandin (oral
treatment for type 2 diabetes), Activelle (combined oral HRT), Innovo
(insulin doser), NovoRapid (rapid-acting insulin analogue), Norditropin,
Simplexx (pen system for liquid growth hormone), Novofem (a low-
dose sequential combined oral HRT), InnoLet (insulin delivery system
for users with poor eyesight, InDuo (combined blood glucose monitor
and insulin injection system), and a few more products.
Today, Novo Nordisk has the broadest diabetes product portfolio in the
industry. They also have a leading position in areas such as haemostasis
management, growth disorders and hormone replacement therapy.
Compound/indication Stage
NovoMix� 50 and 70 Submitted
Type 1 and 2 diabetes
Vagifem� Phase 3
Hormone replacement therapy
Levemir� (Insulin detemir) Phase 3
Type 1 and 2 diabetes
NovoSeven�, Line extension: Trauma Phase 3
Bleeding in emergencies, Trauma
NovoSeven�, Line extension: Phase 3
Intra-cerebral haemorrhages
Bleeding in emergencies,
Intra-cerebral haemorrhages
Activelle� Phase 3
Hormone replacement therapy
AERx� iDMS Phase 2
Type 1 and 2 diabetes
NovoSeven� Phase 2
Elective Surgery, Cardiac Surgery
NovoSeven� Phase 2
Bleeding in emergencies, Traumatic brain injury
NovoSeven� Phase 2
Spinal surgery
NovoSeven� Phase 2
Line extension: Variceal bleedings
Bleeding in emergencies,
Upper gastrointestinal bleeds, cirrhotic patients
Liraglutide (NN2211) Phase 2
Type 2 diabetes
IL-21 Phase 1/2
Malignant melanoma, Cancer
rFXIII, Cardiac surgery Phase 1
Elective Surgery, Cardiac Surgery
NN344 Phase 1
Type 1 and 2 diabetes
HOME
THIS ARTICLE IS FOR YOUR REFERENCE ONLY. PUBLISHER
DOES NOT GUARANTEE ITS ACCURACY. SOME
INFORMATION MAY ALSO BE OUTOFDATED. SOURCE
NOVO NORDISK ONLINE PUBLICATIONS NOVEMBER 30
2005
Novo Nordisk was created in 1989 through a merger between two
Danish companies: Novo Industri A/S and Nordisk Gentofte A/S. In
1941, Novo launches its first enzyme, trypsin, extracted from the
pancreas of animals and used for bating leather before tanning. In 1946,
Nordisk develops Isophane insulin (NPH), a neutral insulin with
prolonged action. In 1947 Novo Norkdisk luanched its first
fermentation product Penicillin Novo. In 1953, Nova Nordisk lauched
Lente - a long-acting insulin suspension. In 1973, Novo Norkdisk
marketed Nanormon growth hormone for the treatment of growth
hormone insufficiency. It also introduced Monocomponent (MC) insulin.
In 1982, Novo Norkdisk launched human monocomponent insulin - the
first insulin preparation idential to human insulin. It is extracted from the
pancreas of pigs and converted to human insulin. In the last two
decades, they developed and launched various products including
NovoPen (an injection system, Norditropin (genetically engineered
human growth hormone), NovoLet (prefilled insulin syringe),
NovoSeven (treatment of haemophilia), NovoNorm/Prandin (oral
treatment for type 2 diabetes), Activelle (combined oral HRT), Innovo
(insulin doser), NovoRapid (rapid-acting insulin analogue), Norditropin,
Simplexx (pen system for liquid growth hormone), Novofem (a low-
dose sequential combined oral HRT), InnoLet (insulin delivery system
for users with poor eyesight, InDuo (combined blood glucose monitor
and insulin injection system), and a few more products.
Today, Novo Nordisk has the broadest diabetes product portfolio in the
industry. They also have a leading position in areas such as haemostasis
management, growth disorders and hormone replacement therapy.
Compound/indication Stage
NovoMix� 50 and 70 Submitted
Type 1 and 2 diabetes
Vagifem� Phase 3
Hormone replacement therapy
Levemir� (Insulin detemir) Phase 3
Type 1 and 2 diabetes
NovoSeven�, Line extension: Trauma Phase 3
Bleeding in emergencies, Trauma
NovoSeven�, Line extension: Phase 3
Intra-cerebral haemorrhages
Bleeding in emergencies,
Intra-cerebral haemorrhages
Activelle� Phase 3
Hormone replacement therapy
AERx� iDMS Phase 2
Type 1 and 2 diabetes
NovoSeven� Phase 2
Elective Surgery, Cardiac Surgery
NovoSeven� Phase 2
Bleeding in emergencies, Traumatic brain injury
NovoSeven� Phase 2
Spinal surgery
NovoSeven� Phase 2
Line extension: Variceal bleedings
Bleeding in emergencies,
Upper gastrointestinal bleeds, cirrhotic patients
Liraglutide (NN2211) Phase 2
Type 2 diabetes
IL-21 Phase 1/2
Malignant melanoma, Cancer
rFXIII, Cardiac surgery Phase 1
Elective Surgery, Cardiac Surgery
NN344 Phase 1
Type 1 and 2 diabetes
HOME
THIS ARTICLE IS FOR YOUR REFERENCE ONLY. PUBLISHER
DOES NOT GUARANTEE ITS ACCURACY. SOME
INFORMATION MAY ALSO BE OUTOFDATED. SOURCE
NOVO NORDISK ONLINE PUBLICATIONS NOVEMBER 30
2005